ArticleClinical journal of gastroenterology2021

Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report.

Shimpei Eguchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.